Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Valeant Pharma target lowered to $18 at RBC Capital Mkts — Slightly revising 2017 estimates following refinancing and Siliq changes (10.71)RBC Capital Mkts lowers their VRX tgt to $18 from $21. They have revised their outlook due to the recent VRX financing and accounting treatment for Siliq revenues. While their revenue forecasts have increased due to Siliq, Adj. EBITDA forecasts have declined slightly. Following a modest increase in net debt, their price target declines to $18; Sector Perform.</td> </tr></table>"